Business Context and Reporting Period
This Form 8-K filing by 22nd Century Group, Inc. (Nasdaq: XXII) reports material events occurring on February 27, 2023, and March 3, 2023. The company, incorporated in Nevada, operates in the biopharmaceutical sector and is headquartered in Buffalo, New York.
Key Financial Metrics and Agreements
The filing details a significant capital raise and debt restructuring executed on March 3, 2023:
- Senior Secured Debentures: The company sold 7% Original Issue Discount Senior Secured Debentures with an aggregate principal amount of $21,052,632 for a total purchase price of $20,000,000.
- Warrants Issued:
- JGB Warrants: Warrants to purchase up to 5,000,000 shares of common stock at an exercise price of $1.275 per share (50% premium to VWAP).
- Omnia Warrants: Warrants to purchase up to 675,000 shares of common stock at an exercise price of $0.855 per share.
- Subordinated Promissory Note: The company refinanced existing notes into a new Subordinated Note with a principal amount of $2,864,767 in favor of Omnia Ventures, LP.
- Interest Rates:
- Debentures: 7% per annum (payable in cash or stock).
- Subordinated Note: 26.5% per annum (payable in-kind/PIK).
- Liquidity Covenants: The company is required to maintain at least $7,500,000 in a separate account on its balance sheet.
Material Changes and Executive Appointments
Debt Restructuring: The Subordinated Note refinanced two prior secured promissory notes totaling $2,500,000 (a $1,000,000 note from October 2021 and a $1,500,000 note from January 2022) assumed during the acquisition of GVB Biopharma.
Executive Appointment: On February 27, 2023, Peter Ferola was promoted to Chief Legal Officer, effective immediately. He previously served as General Counsel since November 2022.
- Compensation: Base salary of $422,000, with eligibility for an annual cash bonus and equity award each valued at up to 100% of base salary.
- Term: Employment agreement runs until October 1, 2025.
- Severance: Entitled to 12 months of base salary continuation if terminated without Cause or for Good Reason.
Outlook, Risks, and Contingencies
Covenants and Restrictions: The Debentures include restrictive covenants limiting the company's ability to incur additional indebtedness, create liens, make investments, pay dividends, or enter into affiliate transactions. The company must also meet certain quarterly revenue targets.
Prepayment and Exit Fees:
- Exit Payment: A 5% fee ($1,052,632) is payable on the maturity date (March 3, 2026) or upon full repayment.
- Prepayment Premium: If redeemed after March 3, 2024, a 3% prepayment premium applies to the outstanding principal balance.
- Change in Control: A change in control may trigger mandatory prepayment of the Debentures.
Default Risks: Obligations under the Debentures can be accelerated upon customary events of default, requiring payment of the Prepayment Amount plus liquidated damages.
Financial Guidance: The filing text does not provide specific revenue or earnings guidance for future periods, though it notes the requirement to maintain quarterly revenue targets as a covenant.
Key Facts for Investor Verification
- Verify the company's ability to maintain the $7,500,000 liquidity covenant required by the new Debentures.
- Confirm the impact of the 26.5% PIK interest on the Subordinated Note on future cash flow and balance sheet liabilities.
- Assess the dilution impact of 5,675,000 total warrants issued (JGB and Omnia) upon exercise.
- Review the specific quarterly revenue targets mandated by the Debenture agreement to gauge operational risk.
- Monitor the company's compliance with restrictive covenants regarding additional debt and dividend payments.